Recent Quotes (30 days)

You have no recent quotes
chg | %

Angel Biotechnology Holdings Plc  

(Public, LON:ABH)   Watch this stock  
Find more results for ABH
Feb 8 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/899,627.00
Mkt cap 1.89M*
P/E     -
Div/yield     -
EPS     -
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2012
Net profit margin -267.48% -
Operating margin -267.01% -
EBITD margin - -
Return on average assets -220.32% -
Return on average equity -676.22% -
Employees 37 -
CDP Score - -


Canary Wharf, 15 Canada Square
United Kingdom - Map

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Angel Biotechnology Holdings Plc is a specialist biopharmaceutical manufacturing company. The Company is engaged in the manufacture and supply of biologics, biological products whose active ingredients cannot be chemically synthesized. The Company supplies the biopharmaceuticals contract manufacturing sector of the biologics market and within that sector focuses on the early-stage drug development work, such as chemistry, manufacturing and controls, and pre-clinical studies, along with drug products for Phases I, II and III of clinical trials. The Company specializes in the manufacture and development of recombinant proteins, cellular therapies and stem cells, antibodies and viruses. The Company operates out of two sites: Pentlands Science Park near Edinburgh and Cramlington near Newcastle upon Tyne. On May 9, 2012, the Company acquired assets of an biomaterial and collagen manufacturing business, through its newly formed and wholly owned subsidiary, Angel Biomedical Ltd (ABL).